

# JOURNAL OF HEPATOLOGY

The Home of Liver Research

VOLUME 71, ISSUE 3, PAGES 449–640

## FROM THE EDITOR'S DESK

### From the Editor's Desk

R. Moreau, R. Bataller, T. Berg, S. Lotersztajn, J. Zucman-Rossi and R. Jalan 449

## EDITORIAL

Residual risk of HCC during long-term oral nucleos(t)ide analogues (NUCs) in patients with CHB – Is one NUC better than the other?

G.L.-H. Wong and P. Lampertico 453

## RESEARCH ARTICLES

### Viral Hepatitis

A multicenter study of entecavir vs. tenofovir on prognosis of treatment-naïve chronic hepatitis B in South Korea

S.U. Kim, Y.S. Seo, H.A. Lee, M.N. Kim, Y.R. Lee, H.W. Lee, J.Y. Park, D.Y. Kim, S.H. Ahn, K.-H. Han, S.G. Hwang, K.S. Rim, S.H. Um, W.Y. Tak, Y.O. Kweon, B.K. Kim and S.Y. Park 456

The burden of hepatitis E among patients with haematological malignancies: A retrospective European cohort study

J. von Felden, L. Alric, S. Pischke, C. Aitken, S. Schlabe, U. Spengler, M.T. Giordani, P. Schnitzler, D. Bettinger, R. Thimme, A. Xhaard, M. Binder, F. Ayuk, A.W. Lohse, J.J. Cornelissen, R.A. de Man and V. Mallet 465

Sustained virologic response to direct-acting antiviral therapy in patients with chronic hepatitis C and hepatocellular carcinoma: A systematic review and meta-analysis

F. Ji, Y.H. Yeo, M.T. Wei, E. Ogawa, M. Enomoto, D.H. Lee, E. Iio, J. Lubel, W. Wang, B. Wei, T. Ide, C.M. Preda, F. Conti, T. Minami, R. Bielen, H. Sezaki, M. Barone, P. Kolly, P.-s. Chu, V. Virlogeux, D. Eurich, L. Henry, M.B. Bass, T. Kanai, S. Dang, Z. Li, J.-F. Dufour, F. Zoulim, P. Andreone, R.C. Cheung, Y. Tanaka, N. Furusyo, H. Toyoda, A. Tamori and M.H. Nguyen 473

Patient-reported symptoms during and after direct-acting antiviral therapies for chronic hepatitis C: The PROP UP study

D.M. Evon, S. Sarkar, J. Amador, A.S. Lok, R.K. Sterling, P.W. Stewart, B.B. Reeve, M. Serper, N. Reau, K. Rajender Reddy, A.M. Di Bisceglie, D.R. Nelson, C.E. Golin, J.K. Lim and M.W. Fried 486

A pilot study of safety and efficacy of HCV retreatment with sofosbuvir/velpatasvir/voxilaprevir in patients with or without HIV (RESOLVE STUDY)

E. Wilson, E. Covert, J. Hoffmann, E. Comstock, B. Emmanuel, L. Tang, J. Husson, J. Chua, A. Price, P. Mathur, E. Rosenthal, S. Kattakuzhy, H. Masur and S. Kottlil 498

### Cirrhosis

Longitudinal neurometabolic changes in the hippocampus of a rat model of chronic hepatic encephalopathy

O. Braissant, V. Rackayová, K. Pierzchala, J. Grosse, V.A. McLin and C. Cudalbu 505

### Cancer

Pravastatin combination with sorafenib does not improve survival in advanced hepatocellular carcinoma

J.-L. Jouve, T. Lecomte, O. Bouché, E. Barbier, F. Khemissa Akouz, G. Riachi, E. Nguyen Khac, I. Ollivier-Hourmand, M. Debette-Gratien, R. Faroux, A.-L. Villing, J. Vergniol, J.-F. Ramee, J.-P. Bronowicki, J.-F. Seitz, J.-L. Legoux, J. Denis, S. Manfredi, J.-M. Phelip and on behalf of PRODIGE-11 investigators/collaborators 516

Models estimating risk of hepatocellular carcinoma in patients with alcohol or NAFLD-related cirrhosis for risk stratification

G.N. Ioannou, P. Green, K.F. Kerr and K. Berry 523

Arterial subtraction images of gadoxetate-enhanced MRI improve diagnosis of early-stage hepatocellular carcinoma

D.H. Kim, S.H. Choi, J.H. Byun, J.H. Kang, Y.-S. Lim, S.J. Lee, S.Y. Kim, H.J. Won, Y.M. Shin and P.-N. Kim 534

Nivolumab in advanced hepatocellular carcinoma: Sorafenib-experienced Asian cohort analysis

T. Yau, C. Hsu, T.-Y. Kim, S.-P. Choo, Y.-K. Kang, M.-M. Hou, K. Numata, W. Yeo, A. Chopra, M. Ikeda, R. Kuromatsu, M. Moriguchi, Y. Chao, H. Zhao, J. Anderson, C.D. Cruz and M. Kudo 543

### Molecular and Cell Biology

Fetal origin confers radioresistance on liver macrophages via p21<sup>cip1</sup>/WAF1

R. Soysa, S. Lampert, S. Yuen, A.N. Douglass, W. Li, K. Pfeffer and I.N. Crispe 553

### Cholestasis and Autoimmune Diseases

Contributing factors and outcomes of burn-associated cholestasis

C. de Tymowski, F. Dépret, S. Soussi, M. Nabila, T. Vauchel, M. Chaussard, M. Benyamina, A. Ferry, A. Cupaciu, M. Jully, H. Oueslati, A. Fratani, M. Coutrot, P. Sogni, M. Mimoun, M. Chaouat, A.-M. Zagdanski, E. De Kerviler, A. Mebazaa, R. Moreau, V. Mallet, M. Legrand and for the PRONOBURN group 563

## Genetic and Metabolic Diseases

Activated hepatic stellate cells and portal fibroblasts contribute to cholestatic liver fibrosis in *MDR2* knockout mice

T. Nishio, R. Hu, Y. Koyama, S. Liang, S.B. Rosenthal, G. Yamamoto, D. Karin, J. Baglieri, H.-Y. Ma, J. Xu, X. Liu, D. Dhar, K. Iwaisako, K. Taura, D.A. Brenner and T. Kisseleva 573

Natural history of histologically proven alcohol-related liver disease: A systematic review

R. Parker, G.P. Aithal, U. Becker, D. Gleeson, S. Masson, J.I. Wyatt, I.A. Rowe and on behalf of the WALDO study group 586

Genetic studies of abdominal MRI data identify genes regulating hepcidin as major determinants of liver iron concentration

H.R. Wilman, C.A. Parisinos, N. Atabaki-Pasdar, M. Kelly, E.L. Thomas, S. Neubauer, IMI DIRECT Consortium, A. Mahajan, A.D. Hingorani, R.S. Patel, H. Hemingway, P.W. Franks, J.D. Bell, R. Banerjee and H. Yaghootkar 594

## REVIEWS

Return to sender: Lymphocyte trafficking mechanisms as contributors to primary sclerosing cholangitis

M. de Krijger, M.E. Wildenberg, W.J. de Jonge and C.Y. Ponsioen 603

Molecular and histological correlations in liver cancer

J. Calderaro, M. Ziol, V. Paradis and J. Zucman-Rossi 616

## LETTERS TO THE EDITOR

Unveiling the depletion of Kupffer cells in experimental hepatocarcinogenesis through liver macrophage subtype-specific markers

S. Lefere, H. Degroote, H. Van Vlierberghe and L. Devisscher 631

Reply to: "Unveiling the depletion of Kupffer cells in experimental hepatocarcinogenesis through liver macrophage subtype-specific markers"

K. Borst, T. Graalman and U. Kalinke 633

Liver transplantation using hepatitis B core positive grafts: Which is the optimal antiviral prophylaxis?

E. Cholongitas and G.V. Papatheodoridis 635

Reply to "Liver transplantation using hepatitis B core positive grafts: Which is the optimal antiviral prophylaxis?"

T. Wong and J. Fung 636

Are liver transplant centres critical for the critically ill patient with cirrhosis?

A. Majumdar, S.K. Roberts and D. Pilcher 637

Reply to: "Prevalence and short-term mortality in a national US cohort with acute-on-chronic liver failure"

R. Hernaez, J.R. Kramer, Y. Liu and F. Kanwal 638

---

## Registration of Clinical Trials

The *Journal of Hepatology* endorses the policy of the WHO and the International Committee of Medical Journal Editors (ICMJE) on the registration of clinical trials. Therefore, any trial that starts recruiting on or after July 1, 2005 should be registered in a publicly owned, publicly accessible registry and should satisfy a minimal standard dataset. Trials that started recruiting before that date will be considered for publication if registered before September 13, 2005.

More detailed information regarding clinical trials and registration can be found in *New Engl J Med* 2004;351:1250–1251 and *New Engl J Med* 2005;352:2437–2438.

Cover image: Models estimating risk of hepatocellular carcinoma in patients with alcohol or NAFLD-related cirrhosis for risk stratification, by George N. Ioannou *et al.* on pp. 523–533 in this issue.

Cover design: The illustration represents the model ("machine") that estimates HCC risk in patients with alcohol-related (ALD) cirrhosis or non-alcoholic (NAFLD) cirrhosis, illustration by Elia Maru Studio.